



# **TOP 10 PHARMACEUTICAL COMPANY PARTNERS WITH TAYLOR & FRANCIS TO POWER AI- DRIVEN RESEARCH & INNOVATION**



**Taylor & Francis**  
an informa company



A top 10 pharmaceutical organisation has been at the forefront of groundbreaking research in oncology, immunology, and neuroscience delivering lifesaving medicines to patients, is always looking for ways to improve patient outcomes. While exploring ways to integrate artificial intelligence into its research workflows to accelerate drug discovery and improve health outcomes they faced a critical challenge: accessing high-quality, verified scientific content that could be legally and ethically incorporated into proprietary AI tools while maintaining rigorous standards for compliance and data integrity.

Taylor & Francis addressed this need through a pioneering three-year AI rights license, the publisher's first-ever agreement of its kind for internal use within the pharmaceutical industry. This landmark deal grants the top 10 pharmaceutical organisation the ability to integrate Taylor & Francis's trusted, verified research directly into its internal AI systems, ensuring that the company's AI-driven research is built on a foundation of credible, validated scientific knowledge while maintaining full compliance with intellectual property and data governance requirements.

Marc Iacono, Vice President of Corporate Markets at Taylor & Francis shared:



*The pace of change is accelerating with the development of artificial intelligence. As a publisher, our mission is to foster human progress through knowledge, and we've had to explore different methods of interaction with our content to continue that mission. The approach we've developed provides a clear outline of the terms of use and limits the restrictions to offer the most value from the integration of the Taylor & Francis data sets in a user-friendly manner and provides post-adoption support and guidance to ensure the content delivers maximum impact.*

A representative from the top 10 pharmaceutical company added



*Utilizing established academic publishers like Taylor & Francis offers several key benefits: ensuring content quality through peer review, providing an initial layer of trust due to adherence to high scholarly standards, granting access to a specialized and authoritative depth of current research, and guaranteeing the long-term permanence and accessibility of published materials essential for consistent research. Verified information reduces the risk of errors, allowing for more confident decision-making while ensuring the organization meets necessary regulatory and industry compliance requirements. The primary value is the ability to leverage vast amounts of high-quality, structured data to improve AI model accuracy and output.*

The result is a transformative partnership that enables them to confidently advance their AI capabilities in pharmaceutical research and development. This agreement not only accelerates the innovation pipeline but also establishes a new standard for how leading publishers and pharmaceutical companies can collaborate to enable responsible AI development. By combining the pharmaceutical companies research expertise with Taylor & Francis's authoritative content, this partnership demonstrates how the industry can harness AI's potential while upholding the highest standards of scientific integrity and ethical data use.

A representative from the top 10 pharmaceutical company said:

“

*Speed is critical to staying competitive and saving lives; licensing trusted content allows researchers to skip the “noise” and focus on proven data, streamlining the path to new therapies.*



Now, with legal and ethical access to the highest quality verified health research the top 10 pharmaceutical organisation will be able to address the challenges they faced when they first integrated artificial intelligence into their research workflows. Access to the content, through their internal AI, will enable them to accelerate drug discovery, speed up the time it takes to bring new medicines to market. This will support the overall aim of both organisations in this industry, to improve overall patient outcomes.





Taylor & Francis  
an informa company

